Short title: Early menopause and type 2 diabetes risk -meta-analysis.
Introduction
Menopause is chronically determined by the completion of 12 months after the final menstrual period. It is the consequence follicular depletion leading to estrogen deficiency 1 . The average age at menopause is 50-52 years 2 . However, approximately 10% of the female population enter menopause before 45 years, a condition termed "early" or "premature" menopause 3 . About 1% of women enter menopause under the age of 40 (0.1% under the age of 30), a condition termed "premature ovarian insufficiency" (POI) 3, 4 . Except of the vasomotor symptoms affecting the woman's quality of life, transition to menopause has been also associated with a potential higher cardiovascular (CVD) risk, mainly attributed to a more atherogenic lipid profile, central adiposity and glucose intolerance [5] [6] [7] [8] .
Both early menopause (EM) and POI have been associated with increased risk of death and CVD in recent meta-analyses 9, 10 . With respect to glucose metabolism, the true effect of endogenous hormonal milieu during menopause on T2DM risk is controversial, since some, but not all, studies have shown a possible association between EM and increased risk of T2DM [11] [12] [13] [14] . The association of T2DM with increased CVD risk has been welldocumented in both genders, although women with T2DM seem to be at a higher relative CVD risk compared with their male counterparts 15 . However, whether EM or POI per se is associated with increased risk of T2DM is unknown.
The aim of this study was to systematically investigate and meta-analyze the best evidence regarding the association of menopausal age with the risk of developing T2DM. moderate, whereas values >60% were considered as high degree of heterogeneity. 
Results

Descriptive data
The initial search provided 1,851 results, after excluding duplicates, 19 of which were assessed as full texts for eligibility ( Figure 1 ). Of those, six articles were excluded, due to the following reasons: (i) No data on T2DM according to menopausal age (n=1); (ii) No data on EM (n=3); (iii) Non-English language (n=1); (iv) Referral to another paper already included in the analysis (n=1). Thirteen studies were included in the qualitative and quantitative analysis [11] [12] [13] [14] [18] [19] [20] [21] [22] [23] [24] [25] [26] . The excluded studies and the reasons for their exclusion are available in Supplementary Table 3 . The studies were published between 2013 and 2017. The countries in which they were conducted were: China (n=5), USA (n=2), India (n=1), Japan (n=2), Vietnam (n=1) and Netherlands (n=1). One study was conducted in more than one country (in Europe). The number of participants ranged from 100 to 124,379, yielding a total number of 191,762 postmenopausal women, with 21,664 cases of T2DM. The mean age of participants was 62.6±7.6 years (data available from nine studies) and mean BMI was 23.9±3.8 kg/m 2 (data available for seven studies).
Diagnosis of T2DM was set by various methods. Fasting plasma glucose (FPG) ≥126 mg/dl (7 mmol/l) or glycated hemoglobin (HbA 1c ) ≥6.5% or plasma glucose ≥200 mg/dl (11.1 mmol/l) at 2 hours, after an oral glucose tolerance test (OGTT) were used in eight studies 12, 14, 18, 21, 22, [24] [25] [26] . Of note, in one study OGTT was performed with a glucometer 20 and in another study the method of T2DM diagnosis was not defined 13 . In the remaining studies, the diagnosis was derived from self-reports, health care reports, hospital admissions or history of anti-diabetic medication use 11, 19, 23 . With respect to the type of menopause, five studies included only women with natural menopause 12, 13, 22, 24-26 , four included mixed populations (9-39% of which with surgical menopause) 11, 14, 18, 19, 23 and in three studies [20] [21] [22] the type of menopause was not clearly defined. No data on prediabetes (defined either as "impaired fasting glucose" or "impaired glucose tolerance") were available. The descriptive characteristics of the studies' participants are presented in Tables 1 and 2 .
Comparison of women with EM with those with normal menopausal age
Women with EM displayed a higher risk of developing T2DM compared with women with normal menopausal age (>45 years) including also those with late menopausal age (12 studies, four prospective cohorts) 11-14, 18, 19, 21-26 Figure 3 ). A variation with respect to the upper limit of normal menopausal age must be noted (ranging from 49 to 55, mostly 52-55). After excluding three studies having used the age of 49 or 50 years as the upper limit of normal menopausal age, the OR of the remaining studies remained significant (1.13, 95% CI: 1.03-1.24, p=0.008) 13, 18, 20 .
Comparison of women with POI with those with normal menopausal age
Women with POI demonstrated a higher risk for developing T2DM compared with women with normal menopausal age, including those with late menopausal age (five studies, three prospective cohorts) (OR: 1.53, 95% CI: 1.03-2.27, p=0.035; I 2 : 78%, 
Late menopause
We also investigated for a potential difference between late menopause and normal menopausal age (45-55 years) with respect to T2DM risk (ten studies, four cohorts) 11, 12, 14, 19, [21] [22] [23] [24] [25] [26] . A tendency for a higher risk of T2DM was observed for women with late menopausal age (OR: 1.12, 95% CI: 0.99-1.28, p=0.069; I 2 : 75.1%, p<0.001).
Meta-regression analysis
Mean age of the participants at study entry, BMI, smoking status and level of physical activity were used as predictors of T2DM development. Mean age of the participants appeared to significantly contribute to the impact of the age at menopause on T2DM risk (Q: 7.62, df: 1, p=0.006) ( Figure 6 ). There was no evidence that BMI altered the effect of age at menopause on the risk of T2DM. Meta-regression analysis for smoking status and physical activity was not possible due to the small number of studies or different ways of definition.
Subgroup analysis
Subgroup analysis was performed with regard to race (Asian versus non-Asian populations), type of menopause (surgical versus natural), study design (cohorts versus case-control studies) and the use of hormone replacement therapy (HRT) and / or oral contraceptives (OC). All subgroup analyses were performed in the concept of comparison between women with EM and those with natural menopause (age at menopause 45-55 years) (13 studies). Non-Asian women with EM were still at a higher risk of T2DM compared with those with natural menopause of the same race (OR: 1.25, 95% CI: 1.11-1.41, p<0.001), whereas no such risk was observed for Asian populations (OR: 1.06, 95% CI: 0.92-1.22, p=0.392). However, there was no difference between these two subgroups (p=0.082). The same associations were observed according to the type of study, being significant only for cohort studies (p < 0.001), with no significant betweengroup heterogeneity (p = 0.082). Furthermore, no difference was detected according to the use of HRT and/or OC (p=0.773). With respect to the type of menopause, no subgroup analysis could be conducted, since no distinct data on surgical menopause were available.
Discussion
To the best of our knowledge, this systematic review and meta-analysis including, 191,762 postmenopausal women and 21,664 cases of T2DM, is the first regarding the association between age of menopause and risk of developing T2DM. Both EM and POI are associated with a higher risk of developing T2DM compared with women with natural menopause, an association that was partially affected by age but not BMI. A tendency for a higher risk was also found for women reporting menopause after 55 years of age.
The exact pathogenetic mechanisms underlying the association between premature menopause and T2DM risk cannot be fully elucidated. A possible mechanism is the shorter exposure to endogenous estrogens, taking into consideration the protective role of estrogens on pancreatic β-cell function and insulin resistance. Estradiol, through binding to its receptor alpha (ERα) in β-cells and through the concomitant phosphorylation of extracellular signal-regulated kinases (ERK1/2), regulates insulin biosynthesis and secretion and modulates β-cell survival 27 . EM-or POI-associated glucose intolerance may also be an indirect effect of the metabolic consequences of body fat redistribution due to estrogen deficiency, which leads to increased central adiposity, predisposing to increased insulin resistance 28, 29 . Moreover, menopause-related changes in serum concentrations of other steroid hormones, such as testosterone, as well as those of sex hormone binding globulin (SHBG), may also play a role in the development of T2DM.
Testosterone production by the ovaries is reduced to a lesser extent after menopause, compared with that of estradiol (30% versus 80%) 30 On the other hand, exposure to excessive estrogen plays also a detrimental role in β-cell function, since it leads to overstimulation of ERα, resulting in excessive insulin signaling and, eventually, insulin resistance in liver and muscle 27 . In a meta-analysis of 13 population-based prospective studies, high concentrations of total estradiol were associated with increased risk of T2DM 36 . This may partly explain the tendency of increased T2DM risk in women with menopausal age >55 years, supporting the notion of a U-shape pattern of the effect of estrogen concentrations and duration of exposure on glucose metabolism. Surprisingly, increased body weight seems to be associated with a later age at menopause, which may also explain the tendency of association between late menopause and increased T2DM risk 37, 38 The effect of other sex steroid hormones, such as testosterone, on the age at menopause seems to be negligible 19, 36 , although others have shown an effect of increased androgen concentrations on higher T2DM risk during menopause 39 . The aforementioned meta-analysis showed that postmenopausal women with T2DM have higher estradiol concentrations, compared with those without 30 .
Another plausible explanation of the positive association between premature menopause and T2DM could be the co-existence of risk factors that predispose to both conditions, such as smoking, low physical activity, obesity and socioeconomic status. Smoking, a well-known risk factor for T2DM 40 , has been also associated with a reduction in time to menopause 37 38 , a decrease in size of the ovarian follicle pool 41 and an increase in follicle stimulating hormone (FSH) concentrations 42 . Toxic chemicals released by tobacco use, such as polycyclic aromatic hydrocarbons, may lead to apoptosis of oocytes to insufficient and heterogeneous data regarding the definition and classification of smoking habit in the included studies. Furthermore, low socio-economic status and education are associated with both higher prevalence of T2DM 44 and earlier age at menopause 37 . Conflicting data exist with regard to physical activity, since low physical activity has been associated with both later 37 and earlier 38 age at menopause.
Genetic variants may predispose to an earlier age of the FMP, since they account for approximately 50% of the variation in the age at menopause 45 . Polymorphisms in genes implicated in DNA repair (such as XO1, HELQ, UIMC1, FAM175A, FANCI, TLK1, POLG, PRIM1) and immune function (such as IL11, NLRP11, BAT2) have been associated with an earlier timing of menopause 46 . Whether these polymorphisms predispose to T2DM risk or just to premature aging is unknown. Some DNA repair gene polymorphisms, such as Xeroderma pigmentosum complementation group D (XPD) and human oxoguanine glycosylase 1 (hOGG1), have been recognized as potential mediators in the pathogenesis of T2DM 47 . Mitochondrial dysfunction seems to play a role both in the timing of menopause 46 and the pathogenesis of T2DM 48 . The obscure contribution of a potential genetic predisposition in earlier menopausal age is further supported by the fact that both race and ethnicity do not seem to be significantly associated with the age of menopause in other studies 37 . In general, age at the natural menopause is a result of constellation of both genetic and environmental factors 37 and clear causality cannot be supported by the aforementioned associations. The tendency for an association between late menopause and increased T2DM risk may be partly attributed to age-related metabolic disturbances, such as central obesity and insulin resistance.
The present study has certain limitations. First, the different design of the original studies might have contributed to the relatively high degree of heterogeneity. The main drawback with case-control studies is that they could not ascertain T2DM, the latter being a selfreported diagnosis. However, the meta-analysis includes four cohort-studies, with a follow-up time between 8-10 years; the significance in the results remained after performing a subgroup analysis. Second, the diagnosis of T2DM was set with different methodology in the studies included. However, after performing a separate analysis for the studies that used either FPG, OGTT or HbA 1c concentrations, the association between EM and T2DM remained significant (eight studies); the same was not true for the association between POI and T2DM (two studies). Third, past use of HRT or OC was not reported in five studies. Of note, the percentage of the participants having received HRT or OC was relatively low and the exact duration could not be defined in most studies.
Therefore, it is probable that it did not alter the results, taking also into account the fact that in the remaining eight studies, subgroup analyses did not demonstrate such an effect.
Fourth, in most subjects included, the age of natural menopause was self-reported (defined as 12 months of amenorrhea), which was subjected to recall bias and the nature of cross-sectional design. Moreover, the cause of EM, which may include chemoradiation or oophorectomy, may have had an independent impact on the risk of T2DM.
Unfortunately, no data were available on the exact cause of EM and its impact on T2DM.
Therefore, no subgroup analysis could be performed on this regard. Fifth, we did not use (age-adjusted or unadjusted) OR directly from the included studies. Only absolute numerical data were extracted, except for the study by Binh et al. 20 , to perform comparisons between T2DM and non-T2DM cases in women with EM and normal menopause.
Conclusions
In summary, this systematic review and meta-analysis in postmenopausal women shows that women entering menopause at an earlier age (either <45 or <40 years) have an increased risk of developing T2DM compared with those with menopausal age >45 years.
This should be taken into account in building prognostic models to early detection of T2DM in women, especially in those at high risk status, to necessitate lifestyle intervention strategies and potential pharmaceutical therapy. Well-designed, prospective cohort and interventional studies will further elucidate these issues.
Declaration of interest
Dr. Stevenson has received grants/research support from Abbott, Mylan and Pfizer; consulting fees from Abbott, Mylan and Pfizer; and speaker's honoraria from Abbott, Bayer, Gedeon Richter, Menarini, Mylan, and Pfizer.
The other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. 
